10-Q: Aligos Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Aligos Therapeutics, a clinical-stage biopharmaceutical company, released its first quarter 2024 financial results, highlighting progress in its MASH, CHB, and coronavirus programs.

Summary

• Aligos Therapeutics reported a net loss of $34.9 million for the first quarter of 2024, compared to a net loss of $23.0 million for the same period in 2023.
• The company's revenue from collaborations decreased to $0.3 million from $2.6 million year-over-year, while revenue from customers increased to $0.7 million from $0.1 million.
• Research and development expenses decreased to $16.4 million from $18.1 million year-over-year, and general and administrative expenses decreased to $6.7 million from $8.5 million.
• As of March 31, 2024, Aligos had cash, cash equivalents, and investments totaling $112.7 million.
• The company expects its existing cash, cash equivalents and investments will enable it to fund its operations for at least 12 months following the date the condensed consolidated financial statements are issued.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and funding, the increased net loss and reliance on future funding raise concerns. The sentiment is cautiously optimistic but with significant risks.

Positives

• The company has initiated Phase 2a dosing for its MASH drug candidate, ALG-055009, with topline data expected in the fourth quarter of 2024.
• Clinical trials for the CHB drug candidate, ALG-000184, are ongoing with interim readouts expected throughout the year.
• Aligos has secured $12.3 million in funding from the NIH to support its coronavirus program.
• The company's cash position is expected to fund operations for at least the next 12 months.

Negatives

• The company experienced a significant increase in net loss for the first quarter of 2024 compared to the same period in 2023.
• Collaboration revenue decreased substantially year-over-year.
• The company has incurred significant losses since inception and expects to continue to incur losses for at least the next several years.
• The company has never generated revenue from product sales and may never be profitable.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.
• Aligos will require substantial additional financing to achieve its goals, which may not be available on acceptable terms, or at all.
• The company's business is dependent on the successful development of its current and future drug candidates, and delays or failures in clinical trials could materially harm the business.
• The company faces significant competition, and if competitors develop and market products that are more effective, safer, or less expensive, Aligos' commercial opportunities will be negatively impacted.
• If Aligos fails to comply with the continued listing requirements of Nasdaq, its common stock may be delisted.
• The company's drug candidates may cause undesirable side effects or have other properties that could delay or halt their clinical development.
• Aligos depends on collaborations with third parties, and if these collaborations are not successful, the company may not be able to capitalize on the market potential of its drug candidates.
• The company is highly dependent on its key personnel, and if it is not successful in attracting, motivating, and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.

Future Outlook

The company expects its existing cash, cash equivalents and investments will enable it to fund its operations for at least 12 months following the date the condensed consolidated financial statements are issued. Topline data from the Phase 2a trial of ALG-055009 is expected in Q4 2024. Interim readouts from the Phase 1b trial of ALG-000184 are expected throughout the year.

Management Comments

• Management expects to continue to incur additional substantial losses in the foreseeable future as a result of expanded research and development activities.
• Management believes that the company's existing cash, cash equivalents and investments will enable it to fund its operations for at least 12 months following the date the condensed consolidated financial statements are issued.

Industry Context

The announcement comes amid increasing interest and investment in treatments for MASH, CHB, and coronaviruses, reflecting a broader trend in the biopharmaceutical industry to address unmet medical needs in these areas. The company is competing with both large pharmaceutical companies and smaller biotech firms in these spaces.

Comparison to Industry Standards

• Aligos's approach to MASH with ALG-055009, a THRagonist, is competing with Madrigal Pharmaceuticals' resmetirom, which recently received FDA approval, but Aligos is aiming for a best-in-class profile with increased potency and selectivity.
• In the CHB space, Aligos's ALG-000184, a CAM-E, is competing with other companies developing similar drugs, but Aligos is highlighting its potential best-in-class multi-log HBV DNA and RNA reductions.
• For coronaviruses, Aligos's ALG-097558 is positioned as a pan-coronavirus antiviral, competing with other protease inhibitors like Pfizer's Paxlovid, but Aligos is emphasizing its broad activity and lack of need for ritonavir boosting.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the need for additional financing.
• Employees may be affected by the company's financial performance and any potential restructuring or layoffs.
• Customers and collaborators may be interested in the progress of the company's clinical trials and the potential for future products.
• Creditors may be concerned about the company's ability to repay its debts if it does not secure additional funding.

Next Steps

• Continue Phase 2a clinical trial of ALG-055009 for MASH, with topline data expected in Q4 2024.
• Continue Phase 1b clinical trials of ALG-000184 for CHB, with interim readouts expected throughout the year.
• Conduct clinical pharmacology studies for ALG-097558 in the second half of 2024 through the end of 2025.
• Seek additional external funding for the coronavirus program and other programs.

Key Dates

Keywords

MASH, CHB, coronavirus, ALG-055009, ALG-000184, ALG-097558, clinical trials, biopharmaceutical, drug development, licensing, collaboration, hepatitis B, liver disease, antiviral, THR agonist, capsid assembly modulator, protease inhibitor